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(SD = 0.15). CONCLUSION: Results obtained thus far suggest
that the HRQL of CLL patients in remission is high. Patients
utilize the additional categories provided with a 5-level instru-
ment. However, in this case the labelled levels still attracted the
greatest percentage of answers, which may be a function of the
design of the questionnaire.
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OBJECTIVES: Progression-free survival (PFS) has not been vali-
dated as a surrogate endpoint for overall survival (OS) for
anthracycline-based (A) or taxane-based (T) chemotherapy in
metastatic breast cancer (MBC). Using a meta-analytic trial-level
approach, we evaluated the relationship between PFS and OS.
METHODS: A literature review identiﬁed all randomized, con-
trolled A and T trials for MBC. Progression-based endpoints
were classiﬁed by prospective deﬁnitions. Treatment effects were
derived as hazard ratios (HR) for PFS (HRPFS) and OS (HROS)
from trial data (constant rate assumption). The kappa statistic
assessed overall agreement. HROS was predicted from trial HRPFS
using ﬁxed effects models that were internally validated. Sensi-
tivity and subgroup analyses were performed for the constant
rate assumption, PFS deﬁnition, year of last patient recruitment,
and line of treatment. RESULTS: Inclusion criteria were met by
15 A and 16 T trials, allowing 17 A (n = 4155) and 17 T
(n = 5509) comparisons. The direction of HROS and HRPFS
agreed in 25% (A) to 50% (T) (negative) and in 62.5% (A) to
50% (T) (positive) (kappa = 0.71, p = 0.0029 (A); kappa = 0.75,
p = 0.0028 (T)). HRPFS was a signiﬁcant predictor of HROS for A
(p = 0.0019) and T (p = 0.012) in the ﬁxed effects models, with
explained variance (R2) of 0.35 (T) and 0.49 (A). Cross valida-
tion showed that 97% of the 95% prediction intervals crossed
the equivalence line. The direction of predicted HROS agreed with
observed HROS in 82% (A) and 76% (T). Results were robust in
sensitivity and subgroup analyses. CONCLUSION: This analysis
suggests the treatment effect on PFS is signiﬁcantly associated
with the treatment effect on OS. However, prediction of OS
based on PFS is surrounded with uncertainty: Half (A) to one
third (T) of the OS treatment effect variance is explained by the
PFS treatment effect variance. Using limited data, sensitivity and
subgroup analysis did not explain result heterogeneity.
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OBJECTIVES: To evaluate if quality-adjusted survival for tem-
sirolimus (TEMSR) met criteria for minimal clinically important
difference (MCID) in a randomized, outpatient study of ﬁrst-line
treatment of patients with poor-prognosis, advanced renal cell
carcinoma (RCC). In this study TEMSR (25 mg IV once-weekly)
was associated with median 10.9 months overall survival
(OS) compared with median 7.3 months OS for interferon
(IFN) (up to 18 MU subcutaneously thrice weekly (p = 0.008).
METHODS: OS was partitioned into 3 distinct periods: a) time
in serious toxicity (aggregated time in grade 3 or 4 adverse events
(AEs); b) time in progression (based on tumor response assess-
ment); and c) time without symptoms of progression or toxicity
(TWiST). Based on patient-reported responses to the EuroQol
(EQ-5D) at representative time points during each period,
Q-TWiST was estimated as the measure of quality-adjusted sur-
vival. Treatment group differences in Q-TWiST were evaluated in
terms of restricted means, with patient follow-up truncated at the
median of 17.9 months. Variance and covariance were estimated
using bootstrap methods. Following published literature, the
clinical importance of the TEMSR-IFN difference in Q-TWIST
was the percentage obtained when this difference was divided by
mean OS for IFN (the control group). RESULTS: All 626 ran-
domized patients were included in computation of health state
durations. Response rates for the EQ-5D were 87% (260/300)
during progression, 40% (230/570) during toxicity, and 99%
(278/279) during TWiST. Patients in the TEMSR group had 1.3
months greater Q-TWiST than those in the IFN group
(TEMSR = 7.0 months vs. IFN = 5.7 months; p = 0.0015). The
MCID was 14.8% (1.3 months divided by 8.8 months [IFN
mean OS]), which is within the published range of 10–15% for
MCID in cancer trials. CONCLUSION: Patients with advanced
RCC receiving TEMSR met criteria for clinically important
improvement in quality-adjusted survival.
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OBJECTIVES: The MABEL study is an open label, uncontrolled,
multi-centre, study of cetuximab in combination with irinotecan
in patients with EGFR expressing mCRC and having progressed
on a recent irinotecan-based treatment regimen. A study objec-
tive was to assess quality of life (QoL). This abstract will report
on ﬁndings on 126 patients from 28 UK sites. METHODS: QoL
was assessed using the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) and the EQ-5D. The QLQ-C30 questionnaire com-
prises 30 items, organised into global health status, functionality,
symptomatology and single items. The EQ-5D questionnaire
consists of the EQ-5D descriptive system and the Visual Ana-
logue Scale (VAS). QoL changes were assessed on patients with a
baseline and at least one post-baseline assessment. RESULTS: At
the 6 week assessment, 88 [69.8%] patients completed at least
one QoL item, with 71 [56.3%] patients at 12 weeks, and 41
[32.5%] patients at the end of the study visit. Given the loss of
two thirds of data by the end of study, the following results will
assess data over a 12 week period. Between baseline and 12
weeks the EORTC QLQ-C30 global health score increased
slightly from 65.3–68.9. Symptomatic scales reported a similar
trend with the exception of diarrhoea and ﬁnancial difﬁculties
single items. The EQ-5D index and VAS also reported a trend for
a slight improvement between baseline (0.73 and 0.90 respec-
tively) and 12 weeks (0.77 and 0.93 respectively.) CONCLU-
SION: It is important to consider these results in context of
patient prognosis and treatment administered. The data suggests
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